Lonza’s first-half core EBITDA gains 16.5%

2022.07.22 08:18

FILE PHOTO: The logo of Swiss pharmaceutical group Lonza is seen at its headquarters in Basel, Switzerland March 2, 2020. REUTERS/Arnd Wiegmann

By Ludwig Burger

(Reuters) – Swiss drug contract manufacturer Lonza said first-half core earnings gained 16.5% on strong demand from drugmakers.

First-half core earnings – adjusted for interest, tax, depreciation and amortisation – (EBITDA) rose to 987 million Swiss francs ($1.02 billion), it said in a statement on Friday. That was above an analyst consensus of about 940 million.

Source